Evidence map›Paper›PMID 39711503›Full record

ArticleCancer medicine2024

Beyond BRAF

Xue Tang, Ju Gao, Xia Guo, Zhi Wan, Jing-Jing Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xue TangDepartment of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Ju GaoDepartment of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Xia GuoDepartment of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-9283-3274
Zhi WanDepartment of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Jing-Jing SunDepartment of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.

Funding

Medical Research Project of Sichuan Medical Association S22023
6 · The paper itself

Abstract

backgroundLangerhans cell histiocytosis (LCH) is the most prevalent histiocytic disorder in pediatric populations, with a highly heterogeneous clinical presentation. Currently, the correlation between clinical phenotypes and molecular alterations in childhood LCH, besides the BRAF

methodsThis study presented data on 33 pediatric LCH patients treated at our center who exhibited various molecular alterations other than the BRAF

resultsA total of 309 pediatric LCH patients with molecular alterations beyond BRAF

conclusionsPediatric LCH patients often carry recurrent somatic MAP2K1 and BRAF mutations, which are associated with clinical manifestations.

Indexed as

Histiocytosis, Langerhans-CellMutationProto-Oncogene Proteins B-rafAdolescentChildChild, PreschoolFemaleHumansInfantMaleMAP Kinase Kinase 1PhenotypeBRAF protein, humanMAP2K1 protein, humanMAP Kinase Kinase 1Proto-Oncogene Proteins B-rafBRAFchildrenclinical featuresLangerhans cell histiocytosisMA2PK1

Identifiers

PMID39711503
PMCPMC11664316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.